Prezista 75mg available for HIV

PREZISTA (darunavir) tablets by Tibotec
PREZISTA (darunavir) tablets by Tibotec
Prezista (darunavir tablet, from Tibotec Therapeutics) is available as a lower-dose 75mg formulation for the treatment of HIV infection in pediatric patients ≥6 years of age, which received FDA approval in December 2008.  

The approval for pediatric use was based on results from DELPHI, a 24-week, open-label, Phase 2 trial, in which antiretroviral treatment-experienced HIV-1 infected pediatric patients received Prezista co-administered with ritonavir in combination with other antiretroviral agents. At week 24, 74% of patients had a decrease from baseline in plasma HIV-1 RNA viral load.  The proportion of pediatric patients reaching undetectable viral load was 50%.  

Prezista is already approved for the treatment of HIV infection in adult patients in 300mg, 400mg, and 600mg dosage strengths.  

For more information call (877) REACH-TT or visit www.prezista.com.